层粘连蛋白总糖肽增强巨噬细胞肿瘤杀伤功能的机制探讨

目的：探讨层粘连蛋白总糖肽（ＬＮ－Ｇｐｓ）增强巨噬细胞（Ｍψ）杀伤黑色素瘤Ｂ６１－ＭＢＫ细胞作用的机制。方法：将细菌脂多糖（ＬＰＳ，５ＥＵ／ｍｌ），甘露聚糖（Ｍａｎｎａｎ，１０ｍｇ／ｍｌ），ＬＮ－Ｇｐｓ（２００μｇ／ｍｌ）及ＰＢＳ（对照），１００μｌ／孔，分别刺激小鼠腹腔Ｍψ，并于持续刺激６，８，１６，２４，３２，４０ｈ后观察Ｍψ对Ｂ１６细胞的直接杀伤作用及其条件培养基对Ｂ１６细胞的杀伤作用。结果     

Rabbit anti-carbohydrate antibody elicited by the lymphocyte mitogenic glycoprotein from Wistaria floribunda seeds

Rabbit antibody produced in response to the purified mitogenic glycoprotein lectin from Wistaria floribunda seeds (WFM) contains anti-carbohydrate antibody. This antibody, which represents 25% of the total antibody precipitated by the homologous antigen cross-reacts with the glycoprotein hemagglutinating lectins from Sophora japonica (SJL), W. floribunda (WFA) and the glycoprotein bromelain, but not the protein lectin from Maclura pomifera seeds. The cross-reactive reaction is totally abolished by the presence of glycopeptides obtained from SJL. Utilization of a fluorometric binding assay employing fluorescein derivatized glycopeptides from SJL, bromelain, fetuin and ovalbumin, it was found that the total anti-carbohydrate antibody population best reacts with the following carbohydrate structure: MAN alpha 1 leads to 6 MAN alpha 1 leads to 6 MAN beta 1 leads to 4 GLCNAC beta 1 leads to 4 GLCNAC beta 1 leads to Asn. Substitution of the beta-mannosyl moiety at position 3 results in structures not capable of binding to the anti-carbohydrate antibody. This antibody appears to distinguish between those glycan moieties of glycoproteins commonly found in animals from those lacking 3-O-substitution of the beta-mannosyl residue as found in some plant glycoproteins.     

薄芝糖肽联合伐昔洛韦片治疗带状疱疹110例临床疗效观察

目的观察薄芝糖肽联合伐昔洛韦片治疗带状疱疹的临床疗效。方法将110例带状疱疹患者随机分为两组,观察组55例给予薄芝糖肽注射液每次10mg,每天1次;口服伐昔洛韦片每次0．3g,每天2次;对照组55例仅给予口服伐昔洛韦片每次0.3g,每天2次。两组疗程均为14d。观察两组患者治疗的总有效率,疼痛减轻、消逝时间和带状疱疹后神经痛（PHN）发生率。结果观察组及对照组治疗总有效率分别为92．7％、72．7％,观察组疼痛减轻、消逝时间短于对照组。PHN发生率明显低于对照组,差异均有统计学意义（P〈0．05）。结论薄芝糖肽联合伐昔洛韦片能有效治疗带状疱疹。缩短PHN时间,降低PHN的发生率,且疗效优于单用伐昔洛韦片。     

薄芝糖肽临床应用中文文献分析

摘 要 目的：分析薄芝糖肽临床应用情况,为临床合理用药提供参考。方法: 检索中国期刊全文数据库（CNKI）、万方数据库、维普资讯网（VIP）收录的薄芝糖肽相关文献,对薄芝糖肽主要临床应用（同病种文献发表数量大于3篇）及不良反应进行统计和分析。结果: 检索得文献163篇,包含临床应用文献137篇,其中文献发表数大于3篇的病种有尖锐湿疣（9篇）、带状疱疹（6篇）、手足口病（6篇）、寻常型银屑病（6篇）、肺癌（5篇）、小儿反复呼吸道感染（4篇）、乙型肝炎（9篇）,共计45篇。45篇临床应用文献中有32篇（共1 772例）涉及不良反应病例,有49例发生不良反应,发生率为2.77%,以皮肤及其附件损害为主（10例,20.0%）。ADR病例报道11篇,涉及病例数20例,以寒战和发热为主（13例,37.2%）。结论:薄芝糖肽作为辅助用药在临床上主要与其他药物联合应用,能够增强主要治疗药物的疗效,不良反应发生率低且以皮肤及其附件损害为主。     

Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections

PurposeThis study aimed to provide compelling evidence of anti-staphylococcal beta-lactam use for methicillin-susceptible Staphylococcus aureus bloodstream infection (MSSA BSI).Materials and MethodsWe retrospectively collected data on patients with MSSA BSI who were admitted to two academic tertiary-care hospitals from 2010 to 2018. Only patients who received nafcillin, cefazolin, vancomycin, or teicoplanin as definitive therapy were included. The primary outcome was 28-day mortality. To perform unbiased comparisons between both treatments, we used inverse probability of treatment weighting (IPTW) analysis.ResultsA total of 359 patients were divided into two groups based on the definitive therapy used: beta-lactams (n=203), including nafcillin or cefazolin; and glycopeptides (n=156), including vancomycin or teicoplanin. In the IPTW analysis, glycopeptides were associated with significantly increased odds of 28-day mortality (adjusted odds ratio, 3.37; 95% confidence interval, 1.71–6.61; p<0.001). The rate of primary outcome in prespecified subgroups was largely consistent with the main analysis.ConclusionDefinitive therapy with beta-lactams in patients with MSSA BSI was associated with lower 28-day mortality compared to definitive therapy with glycopeptides.